IP Group portfolio company Microbiotica reports promising trial results in ulcerative colitis
MB310, a live biotherapeutic developed by Cambridge-based Microbiotica, achieves 63% remission rate in early study IP Group PLC (LSE:IPO), the London-listed investor in science and technology companies, has announced that portfolio company Microbiotica has reported positive results from a Phase 1b trial of its lead microbiome medicine in ulcerative colitis. The trial met its primary and secondary endpoints, with MB310 demonstrating a strong safety profile, robust engraftment of its eight-strain bacterial consortium and statistically significant clinical improvements compared with placebo.
From OpenAI To SpaceX: The IPO ETF Bet On A 2026 Go-Public Surge
Renaissance IPO ETF (IPO) is rated a buy, anticipating a surge in major IPOs through 2026 to fuel renewed investor interest. IPO's portfolio is heavily growth-oriented, with 94% SMID-cap exposure and a 42% weighting in Information Technology. Despite a high 26.9x P/E, IPO's long-term earnings growth near 32% yields a compelling PEG ratio below 2.
IP Group hails $115m fundraising at Artios as cancer-drug developer accelerates late-stage trials
IP Group PLC (LSE:IPO) has welcomed a major funding milestone at its portfolio company Artios Pharma, after the DNA-damage-response specialist closed an oversubscribed $115 million Series D round that will push two of its most advanced cancer programmes deeper into clinical development. Cambridge-based Artios is developing treatments that target weaknesses in the way cancer cells repair their DNA, a field known as DDR.
IP Group's investments are paying off - ICYMI
IP Group PLC (LSE:IPO) CEO Greg Smith joined Proactive to discuss the company's strategic outlook, recent exits, and high-potential investments. Topics include future royalty streams from obesity drug programs, portfolio realisations, and IP Group's backing of clean tech innovator OXCCU.
IP Group scores another exit as CoreWeave moves to buy Monolith
IP Group PLC (LSE:IPO) has announced that one of its portfolio companies, Monolith, is being acquired by Nasdaq-listed CoreWeave, marking another successful sale from its deeptech investments. The London-listed investment firm, which holds a 12.3% stake in Monolith, said the deal follows recent disposals of other portfolio businesses, Featurespace and Garrison.
IP Group: OXCCU raises £20m to advance sustainable aviation fuel tech
IP Group PLC (LSE:IPO) portfolio company OXCCU has raised £20.75 million in an oversubscribed Series B funding round. The Oxford University spin-out is developing a single-step process to convert waste carbon into sustainable aviation fuel.
IPO pipeline: Here's what's ahead
Dan Primack, Axios business editor, joins 'The Exchange' to discuss Klarna nearing IPO as the IPO market sees a post-Labor Day push.
BLSH Stock: Is Bullish a Good Investment? An IPO ETF Offers a Clue
Bullish (BLSH) just hit the market amid crypto buzz. To size up its near-term path, we map BLSH against the Renaissance IPO ETF (IPO)—a proxy for how fresh listings trade.
IPO: Upgrading To Buy As The IPO Window Cracks Open
The US IPO market is showing renewed strength, with recent successful tech IPOs like CoreWeave and Circle sparking optimism. I am upgrading the Renaissance IPO ETF to a buy, as bullish sentiment returns and the IPO window appears to be opening wider. IPO offers diversified exposure to newly public companies, with a balanced mix of value, blend, and growth, though it remains a higher-risk ETF.
Won't be surprised China's IPO market has a relatively good year: China Renaissance
Andy Maynard of China Renaissance discusses the potential IPO of CATL and says the number of upcoming deals on the Hong Kong stock exchange is "really encouraging".
IPO: Favorable Capital Markets In 2025 Not Yet A Tailwind (Rating Downgrade)
The IPO market has been sluggish for almost three years due to elevated global yields and macroeconomic uncertainties, despite a peak in early 2021. I am downgrading the Renaissance IPO ETF from a buy to a hold due to valuation concerns and mixed technical signals. The ETF's high tech exposure and lack of large-cap stocks increase its cyclical risk, especially with rising market interest rates.
Bill Ackman Weighs Pivot To ETF After Abandoning Closed-End Fund IPO: Report
Bill Ackman, the visionary leader of Pershing Square Capital Management, is making headlines in the financial world with a potential strategic shift from a U.S. closed-end fund IPO to the potential launch of a Pershing Square Exchange-Traded Fund (ETF).
